The Institute for Clinical and Economic Review (ICER) announced plans to review BioMarin Pharmaceutical’s gene therapy for hemophilia A, valoctocogene roxaparvovec.
According to a press release, the Food and Drug Administration is expected to make a decision on the investigational gene therapy later this year.
ICER is accepting feedback on a timeline for the assessment until 5 p.m. Jan. 22.
To learn more, click here.
Click here to read the full press release.